Celcuity Inc. (CELC) Research

Operating as a clinical-stage biotechnology company, Celcuity Inc. is dedicated to pioneering precision cancer treatments for patients across the United States. At the heart of their approach is the CELsignia diagnostic platform, which examines live tumor cells from patients. This innovative system aims to uncover the precise cellular dysfunction fueling an individual's cancer, thereby guiding the selection of the most appropriate targeted therapeutic intervention. Among its pipeline of drug candidates is Gedatolisib, an agent engineered to selectively inhibit class I PI3K isoforms and mammalian target of rapamycin (mTOR). This therapy is being developed specifically for advanced or metastatic breast cancer patients who are hormone receptor positive and HER2-negative. Celcuity is also advancing the CELsignia MP test, a qualitative lab-developed assay designed to quantify HER2, c-Met, and PI3K signaling activity within both breast and ovarian tumor cells. The company secured a licensing agreement with Pfizer, Inc. for the development and commercialization rights pertaining to Gedatolisib. Established in 2011, Celcuity Inc. maintains its corporate headquarters in Minneapolis, Minnesota.

Market snapshot

Symbol
CELC
Price
$87.76
Day change
-0.33%
Market cap
$4.3B
P/E ratio
-22.56x
52-week range
11.275-151.02
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$153.22

Recent news

  • What's Going On With Celcuity Stock On Tuesday?

    Celcuity Inc. (NASDAQ:CELC) on Tuesday reported detailed efficacy and safety findings from the PIK3CA-mutated cohort of its Phase 3 VIKTORIA-1 trial.

  • Celcuity plunges after experimental breast cancer treatment data disappoints

    Celcuity shares slumped 25% , set for their biggest one-day decline, on Tuesday after its experimental breast cancer treatment extended ​the period of time a patient lives without the disease ‌worsening but underperformed a previous trial.

  • Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst

    On Thursday, Celcuity Inc. (NASDAQ:CELC) announced amendments to its Phase 3 VIKTORIA-2 clinical trial evaluating gedatolisib as a first-line treatment for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Peer companies

  • Ascentage Pharma Group International (AAPG)
  • Apogee Therapeutics, Inc. (APGE)
  • CG Oncology, Inc. Common stock (CGON)
  • Centessa Pharmaceuticals plc (CNTA)
  • Disc Medicine, Inc. (IRON)
  • Legend Biotech Corporation (LEGN)
  • Ultragenyx Pharmaceutical Inc. (RARE)
  • Travere Therapeutics, Inc. (TVTX)

Recent insider activity

  • Murphy Polly A. — G-Gift (14048 shares) on 2026-06-10
  • Murphy Polly A. — G-Gift (14048 shares) on 2026-06-10
  • Buller Richard E — G-Gift (12503 shares) on 2026-06-10
  • Buller Richard E — G-Gift (12503 shares) on 2026-06-10
  • Murphy Polly A. — A-Award (1530 shares) on 2026-06-05

Open Celcuity Inc. (CELC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.